BD announces award to NHS Supply Chain Framework Agreement
News Dec 10, 2012
BD (Becton, Dickinson and Company) accepted its successful award to NHS Supply Chain’s National Microbiology Framework Agreement.
NHS Supply Chain provides patient-focused healthcare products and supply chain services to the UK’s National Health Service (NHS). The agreement covers a comprehensive product range that sit within the Microbiology department.
Providing customer focussed supply chain services, giving customers a single point of access to thousands of products nationally, BD’s acknowledged award is a step forward in the changing landscape.
The following product areas will be covered via NHS Supply Chain’s Framework Agreement:
• Microbiological Identification Kits: Biochemical, Agglutination Tests
• Manual Antimicrobial Susceptibility Testing
• Pre-Poured Culture Media and Broth
• Automated Blood Culture
• Automated Identification and Susceptibility Analysers
• Automated Identification of Tuberculosis System
• Plate Streakers
• Automated Identification – Maldi TOF (In partnership with Bruker Daltonics)
For further information about BD’s award to NHS Supply Chain’s National Microbiology Framework Agreement, including when products will be available to purchase and how NHS Supply Chain can support your trust set-up specific products for ordering, please visit: www.supplychain.nhs.uk
Tweak to Technique Could Bolster Disease DetectionNews
A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.READ MORE
Immune Cells That Keep Gut Fungi Under Control IdentifiedNews
Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists.READ MORE
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018